Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors
Germ Cell Tumor
About this trial
This is an interventional treatment trial for Germ Cell Tumor focused on measuring Patients with relapsed non-seminomatous germ-cell tumors (NSGCT)
Eligibility Criteria
Inclusion Criteria: Patients older than 16 years Histologically-proven disseminated (non stage I) NSGCT, or diagnosis of NSGCT based on very elevated serum human chorionic gonadotropin (HCG) and/or alpha fetoprotein (AFP) Relapsed disease classified as good prognosis according to the Memorial Sloan-Kettering Cancer Center (MSKCC) classification criteria: Testicular primary site Prior treatment limited to one program (or 6 or fewer cycles of cisplatin) Either a complete response or a partial response with normal serum AFP and HCG Relapse documented by rising AFP and/or HCG or by a biopsy No previous carcinoma, except basal-cell carcinoma of the skin Adequate renal function: measured or calculated creatinine clearance> 60 ml/min Absolute granulocyte count >= 1,500/mm3, platelets >= 100,000 mm3, bilirubin < 1.5 fold the upper normal value Signed informed consent. Exclusion Criteria: Patients infected by the human immunodeficiency virus (HIV) Patients who do not fit inclusion criteria
Sites / Locations
- Institut Gustave RoussyRecruiting